ViiV Healthcare at IDWeek 2026
Oct 21–24, 2026 Washington, DC ~12k attendees Website
ViiV Healthcare brings 12 presentations to IDWeek 2026 in Washington, and exhibits at Booth 905, BS 1 A, BS 1 B, BS 1 C. Its program centres on long-acting injectable cabotegravir for HIV prevention, including real-world persistence, user experience and expectations for less frequent dosing. It also models the future US burden of HIV and introduces a next-generation integrase inhibitor built to hold up better against resistance.
| Organization | IDWeek 2026 Attendance |
|---|---|
ViiV Healthcare London, UK | |
Pharmaceutical company focused solely on HIV, researching and delivering medicines for people living with HIV or seeking to prevent it. | Booth Exhibiting at Booth 905, BS 1 A, BS 1 B, BS 1 C Thu, Oct 2210am–2pmFri, Oct 2310am–2pmSat, Oct 2410am–2pm Session Thu Oct 22 2:00pm–2:30pm IDBugCrawl: ViiV Session Progress Made Personal: Bringing Long-Acting HIV Treatment and Prevention to Life for the Patients We See Every Day HIV, sexually transmitted infections and viral hepatitisAntimicrobials, resistance and stewardship Poster Fri Oct 23 12:15pm–1:30pm Dolutegravir + Lamivudine in People with HIV-1 Who Are Naive to Antiretroviral Therapy with Baseline Viral Load ≥500,000 c/mL: Systematic Literature Review and Meta-Analysis of Real-World Evidence Poster Fri Oct 23 12:15pm–1:30pm Early Expectations of Cabotegravir Every 4 Month Injections for HIV Pre-Exposure Prophylaxis among Individuals Using Cabotegravir Every 2 Month Injectable Poster Fri Oct 23 12:15pm–1:30pm Human Immunodeficiency Virus (HIV) Testing and Evidence of HIV among Real-World Long-Acting Pre-Exposure Prophylaxis (PrEP) Users in a United States Claims Database: Updated Results from the PrEPFACTS Study Poster Fri Oct 23 12:15pm–1:30pm Immune Recovery Continues to Improve over 5 years with Fostemsavir Despite Emergent gp120 Substitutions Poster Fri Oct 23 12:15pm–1:30pm Modelling the Future Epidemiological and Economic Burden of HIV in the United States: Substantial New Diagnoses and Additional Costs Projected Under Current Care Patterns Poster Fri Oct 23 12:15pm–1:30pm Modelling the impact of scale-up of long-acting injectables for HIV prevention and treatment in the United States (US) Poster Fri Oct 23 12:15pm–1:30pm Racial and Ethnic Differences in Long Acting Cabotegravir for HIV-1 Pre-Exposure Prophylaxis Experience in a US Real-World Cross‑Sectional Study: Results from the CAPTIVATE Study Poster Fri Oct 23 12:15pm–1:30pm Real-world Persistence of Long Acting Cabotegravir for HIV Pre-Exposure Prophylaxis in the United States: Results from the PrEPFACTS Study Using Healthcare Administrative Claims Data Poster Fri Oct 23 12:15pm–1:30pm The Evolution of Integrase Strand Transfer Inhibitors: VH-184, a 3rd-Generation Inhibitor with an Enhanced Resistance Profile Poster Fri Oct 23 12:15pm–1:30pm User Experience Concepts Assessed Among People in the United States Using Long-Acting Injectable Cabotegravir for PrEP in Real-World Care: Results from the CAPTIVATE Study Industry Fri Oct 23 1:15pm–2:00pm |
Instantly find 20 buyers from ViiV Healthcare
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by IDWeek, the Infectious Diseases Society of America (IDSA) or its partner societies (SHEA, HIVMA, PIDS and SIDP). Submit a correction